The current status of prostaglandins as abortifacients
The present use and potential uses of prostaglandins as abortifacients are summarized. Pertinent history, chemistry, prostaglandins' possible role in physiologic and pathologic processes and pharmacologic actions are discussed. The results of natural prostaglandins and their analogues by system...
Gespeichert in:
| Veröffentlicht in: | American journal of obstetrics and gynecology 1975-10, Vol.123 (3), p.306-328 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 328 |
|---|---|
| container_issue | 3 |
| container_start_page | 306 |
| container_title | American journal of obstetrics and gynecology |
| container_volume | 123 |
| creator | Brenner, William E. |
| description | The present use and potential uses of prostaglandins as abortifacients are summarized. Pertinent history, chemistry, prostaglandins' possible role in physiologic and pathologic processes and pharmacologic actions are discussed. The results of natural prostaglandins and their analogues by systemic and intrauterine administration for the purposes of postcoital contraception, menstrual regulation, first- and second-trimester abortion, preoperative dilatation of the cervix, and delivery of patients with death in utero are presented. The only approved method of induction of abortion with prostaglandins, prostaglandin F2α by the intra-amniotic route for the induction of midtrimester abortion, is evaluated and compared to other methods of midtrimester abortion. It was concluded that: (1) the present use of prostaglandins is an important addition to the obstetrician's armamentarium, (2) more effective and/or convenient methods that are useful in patients over a wider gestational age appear to have been defined, and (3) the routine use of prostaglandins for postcoital contraception, menstrual regulation, and first-trimester abortion will require the development of analogues that are more specific as to their abortifacient actions than the natural prostaglandins and/or the development of improved delivery systems. |
| doi_str_mv | 10.1016/0002-9378(75)90205-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_82999090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0002937875902057</els_id><sourcerecordid>82999090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-30924cc38687dee58c5bbbb282d30b78efa546e5a119043a37eb0217d5643ca93</originalsourceid><addsrcrecordid>eNp9UMtOwzAQtBCvUviDHnJCcAis7Ti2L0io4iVV4lLOluNswKhtip0g8fc4pOqRlaX1amdHM0PIjMINBVreAgDLNZfqSoprDQxELg_IhIKWealKdUgme8gpOYvxcxiZZifkWNH0FRNSLj8wc30IuOmy2Nmuj1nbZNvQpuF9ZTe138TMple1ofONdT4h4zk5auwq4sWuT8nb48Ny_pwvXp9e5veL3HFRdjkHzQrneBIja0ShnKhSMcVqDpVU2FhRlCgspRoKbrnEChiVtSgL7qzmU3I58iZBXz3Gzqx9dLhKwrDto1FMaw0aErAYgS4pjwEbsw1-bcOPoWCGtMzg3QxRGCnMX1pGprPZjr-v1ljvj8Z40vpuXGPy-O0xmDj4d1j7gK4zdev_5_8FmEd4QA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>82999090</pqid></control><display><type>article</type><title>The current status of prostaglandins as abortifacients</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Brenner, William E.</creator><creatorcontrib>Brenner, William E.</creatorcontrib><description>The present use and potential uses of prostaglandins as abortifacients are summarized. Pertinent history, chemistry, prostaglandins' possible role in physiologic and pathologic processes and pharmacologic actions are discussed. The results of natural prostaglandins and their analogues by systemic and intrauterine administration for the purposes of postcoital contraception, menstrual regulation, first- and second-trimester abortion, preoperative dilatation of the cervix, and delivery of patients with death in utero are presented. The only approved method of induction of abortion with prostaglandins, prostaglandin F2α by the intra-amniotic route for the induction of midtrimester abortion, is evaluated and compared to other methods of midtrimester abortion. It was concluded that: (1) the present use of prostaglandins is an important addition to the obstetrician's armamentarium, (2) more effective and/or convenient methods that are useful in patients over a wider gestational age appear to have been defined, and (3) the routine use of prostaglandins for postcoital contraception, menstrual regulation, and first-trimester abortion will require the development of analogues that are more specific as to their abortifacient actions than the natural prostaglandins and/or the development of improved delivery systems.</description><identifier>ISSN: 0002-9378</identifier><identifier>EISSN: 1097-6868</identifier><identifier>DOI: 10.1016/0002-9378(75)90205-7</identifier><identifier>PMID: 810025</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Abortifacient Agents ; Abortifacient Agents, Nonsteroidal ; Abortion, Induced ; Administration, Oral ; Amnion ; Animals ; Cervix Uteri - drug effects ; Corpus Luteum - drug effects ; Female ; Haplorhini ; Humans ; Injections ; Injections, Intramuscular ; Injections, Intravenous ; Population ; Pregnancy ; Prostaglandins - pharmacology ; Prostaglandins - physiology ; Prostaglandins E - administration & dosage ; Prostaglandins E - adverse effects ; Prostaglandins E - pharmacology ; Prostaglandins F - administration & dosage ; Prostaglandins F - adverse effects ; Prostaglandins F - pharmacology ; Rats ; Suppositories ; Uterine Contraction - drug effects ; Uterus ; Vagina</subject><ispartof>American journal of obstetrics and gynecology, 1975-10, Vol.123 (3), p.306-328</ispartof><rights>1975</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-30924cc38687dee58c5bbbb282d30b78efa546e5a119043a37eb0217d5643ca93</citedby><cites>FETCH-LOGICAL-c356t-30924cc38687dee58c5bbbb282d30b78efa546e5a119043a37eb0217d5643ca93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0002-9378(75)90205-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/810025$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brenner, William E.</creatorcontrib><title>The current status of prostaglandins as abortifacients</title><title>American journal of obstetrics and gynecology</title><addtitle>Am J Obstet Gynecol</addtitle><description>The present use and potential uses of prostaglandins as abortifacients are summarized. Pertinent history, chemistry, prostaglandins' possible role in physiologic and pathologic processes and pharmacologic actions are discussed. The results of natural prostaglandins and their analogues by systemic and intrauterine administration for the purposes of postcoital contraception, menstrual regulation, first- and second-trimester abortion, preoperative dilatation of the cervix, and delivery of patients with death in utero are presented. The only approved method of induction of abortion with prostaglandins, prostaglandin F2α by the intra-amniotic route for the induction of midtrimester abortion, is evaluated and compared to other methods of midtrimester abortion. It was concluded that: (1) the present use of prostaglandins is an important addition to the obstetrician's armamentarium, (2) more effective and/or convenient methods that are useful in patients over a wider gestational age appear to have been defined, and (3) the routine use of prostaglandins for postcoital contraception, menstrual regulation, and first-trimester abortion will require the development of analogues that are more specific as to their abortifacient actions than the natural prostaglandins and/or the development of improved delivery systems.</description><subject>Abortifacient Agents</subject><subject>Abortifacient Agents, Nonsteroidal</subject><subject>Abortion, Induced</subject><subject>Administration, Oral</subject><subject>Amnion</subject><subject>Animals</subject><subject>Cervix Uteri - drug effects</subject><subject>Corpus Luteum - drug effects</subject><subject>Female</subject><subject>Haplorhini</subject><subject>Humans</subject><subject>Injections</subject><subject>Injections, Intramuscular</subject><subject>Injections, Intravenous</subject><subject>Population</subject><subject>Pregnancy</subject><subject>Prostaglandins - pharmacology</subject><subject>Prostaglandins - physiology</subject><subject>Prostaglandins E - administration & dosage</subject><subject>Prostaglandins E - adverse effects</subject><subject>Prostaglandins E - pharmacology</subject><subject>Prostaglandins F - administration & dosage</subject><subject>Prostaglandins F - adverse effects</subject><subject>Prostaglandins F - pharmacology</subject><subject>Rats</subject><subject>Suppositories</subject><subject>Uterine Contraction - drug effects</subject><subject>Uterus</subject><subject>Vagina</subject><issn>0002-9378</issn><issn>1097-6868</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1975</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UMtOwzAQtBCvUviDHnJCcAis7Ti2L0io4iVV4lLOluNswKhtip0g8fc4pOqRlaX1amdHM0PIjMINBVreAgDLNZfqSoprDQxELg_IhIKWealKdUgme8gpOYvxcxiZZifkWNH0FRNSLj8wc30IuOmy2Nmuj1nbZNvQpuF9ZTe138TMple1ofONdT4h4zk5auwq4sWuT8nb48Ny_pwvXp9e5veL3HFRdjkHzQrneBIja0ShnKhSMcVqDpVU2FhRlCgspRoKbrnEChiVtSgL7qzmU3I58iZBXz3Gzqx9dLhKwrDto1FMaw0aErAYgS4pjwEbsw1-bcOPoWCGtMzg3QxRGCnMX1pGprPZjr-v1ljvj8Z40vpuXGPy-O0xmDj4d1j7gK4zdev_5_8FmEd4QA</recordid><startdate>19751001</startdate><enddate>19751001</enddate><creator>Brenner, William E.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19751001</creationdate><title>The current status of prostaglandins as abortifacients</title><author>Brenner, William E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-30924cc38687dee58c5bbbb282d30b78efa546e5a119043a37eb0217d5643ca93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1975</creationdate><topic>Abortifacient Agents</topic><topic>Abortifacient Agents, Nonsteroidal</topic><topic>Abortion, Induced</topic><topic>Administration, Oral</topic><topic>Amnion</topic><topic>Animals</topic><topic>Cervix Uteri - drug effects</topic><topic>Corpus Luteum - drug effects</topic><topic>Female</topic><topic>Haplorhini</topic><topic>Humans</topic><topic>Injections</topic><topic>Injections, Intramuscular</topic><topic>Injections, Intravenous</topic><topic>Population</topic><topic>Pregnancy</topic><topic>Prostaglandins - pharmacology</topic><topic>Prostaglandins - physiology</topic><topic>Prostaglandins E - administration & dosage</topic><topic>Prostaglandins E - adverse effects</topic><topic>Prostaglandins E - pharmacology</topic><topic>Prostaglandins F - administration & dosage</topic><topic>Prostaglandins F - adverse effects</topic><topic>Prostaglandins F - pharmacology</topic><topic>Rats</topic><topic>Suppositories</topic><topic>Uterine Contraction - drug effects</topic><topic>Uterus</topic><topic>Vagina</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brenner, William E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of obstetrics and gynecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brenner, William E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The current status of prostaglandins as abortifacients</atitle><jtitle>American journal of obstetrics and gynecology</jtitle><addtitle>Am J Obstet Gynecol</addtitle><date>1975-10-01</date><risdate>1975</risdate><volume>123</volume><issue>3</issue><spage>306</spage><epage>328</epage><pages>306-328</pages><issn>0002-9378</issn><eissn>1097-6868</eissn><abstract>The present use and potential uses of prostaglandins as abortifacients are summarized. Pertinent history, chemistry, prostaglandins' possible role in physiologic and pathologic processes and pharmacologic actions are discussed. The results of natural prostaglandins and their analogues by systemic and intrauterine administration for the purposes of postcoital contraception, menstrual regulation, first- and second-trimester abortion, preoperative dilatation of the cervix, and delivery of patients with death in utero are presented. The only approved method of induction of abortion with prostaglandins, prostaglandin F2α by the intra-amniotic route for the induction of midtrimester abortion, is evaluated and compared to other methods of midtrimester abortion. It was concluded that: (1) the present use of prostaglandins is an important addition to the obstetrician's armamentarium, (2) more effective and/or convenient methods that are useful in patients over a wider gestational age appear to have been defined, and (3) the routine use of prostaglandins for postcoital contraception, menstrual regulation, and first-trimester abortion will require the development of analogues that are more specific as to their abortifacient actions than the natural prostaglandins and/or the development of improved delivery systems.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>810025</pmid><doi>10.1016/0002-9378(75)90205-7</doi><tpages>23</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9378 |
| ispartof | American journal of obstetrics and gynecology, 1975-10, Vol.123 (3), p.306-328 |
| issn | 0002-9378 1097-6868 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_82999090 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Abortifacient Agents Abortifacient Agents, Nonsteroidal Abortion, Induced Administration, Oral Amnion Animals Cervix Uteri - drug effects Corpus Luteum - drug effects Female Haplorhini Humans Injections Injections, Intramuscular Injections, Intravenous Population Pregnancy Prostaglandins - pharmacology Prostaglandins - physiology Prostaglandins E - administration & dosage Prostaglandins E - adverse effects Prostaglandins E - pharmacology Prostaglandins F - administration & dosage Prostaglandins F - adverse effects Prostaglandins F - pharmacology Rats Suppositories Uterine Contraction - drug effects Uterus Vagina |
| title | The current status of prostaglandins as abortifacients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T13%3A55%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20current%20status%20of%20prostaglandins%20as%20abortifacients&rft.jtitle=American%20journal%20of%20obstetrics%20and%20gynecology&rft.au=Brenner,%20William%20E.&rft.date=1975-10-01&rft.volume=123&rft.issue=3&rft.spage=306&rft.epage=328&rft.pages=306-328&rft.issn=0002-9378&rft.eissn=1097-6868&rft_id=info:doi/10.1016/0002-9378(75)90205-7&rft_dat=%3Cproquest_cross%3E82999090%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=82999090&rft_id=info:pmid/810025&rft_els_id=0002937875902057&rfr_iscdi=true |